Pages that link to "Q29620051"
Jump to navigation
Jump to search
The following pages link to Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates (Q29620051):
Displaying 50 items.
- TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu (Q21131200) (← links)
- B7-H5 costimulates human T cells via CD28H (Q24295841) (← links)
- A comprehensive overview of targeted therapy in metastatic renal cell carcinoma (Q24606852) (← links)
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer (Q24633070) (← links)
- Role of PD-1 in HIV pathogenesis and as target for therapy (Q24634293) (← links)
- Immunobiology and immunotherapy in genitourinary malignancies (Q26738668) (← links)
- Contemporary Treatment of Metastatic Renal Cell Carcinoma (Q26740863) (← links)
- New targeted treatments for non-small-cell lung cancer - role of nivolumab (Q26740988) (← links)
- PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? (Q26741101) (← links)
- The role of pembrolizumab in the treatment of advanced non-small cell lung cancer (Q26744076) (← links)
- Emerging molecular classifications and therapeutic implications for gastric cancer (Q26745525) (← links)
- Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer (Q26745590) (← links)
- The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints (Q26745842) (← links)
- Lymphocyte-activation gene-3, an important immune checkpoint in cancer (Q26746209) (← links)
- Role of the tumor microenvironment in mature B-cell lymphoid malignancies (Q26748775) (← links)
- Immunotherapy for cancer in the central nervous system: Current and future directions (Q26750765) (← links)
- Clinical utility of nivolumab in the treatment of advanced melanoma (Q26751268) (← links)
- Advances in targeted and immunobased therapies for colorectal cancer in the genomic era (Q26751344) (← links)
- Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects (Q26753082) (← links)
- Genetics and biology of pancreatic ductal adenocarcinoma (Q26765438) (← links)
- The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response (Q26766066) (← links)
- Advances in immunotherapy for melanoma (Q26768558) (← links)
- PD-1/PD-L1 blockade in cancer treatment: perspectives and issues (Q26768641) (← links)
- Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer (Q26769713) (← links)
- Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment (Q26769963) (← links)
- Novel technologies and emerging biomarkers for personalized cancer immunotherapy (Q26770780) (← links)
- Viro-immune therapy: A new strategy for treatment of pancreatic cancer (Q26774641) (← links)
- Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect (Q26775578) (← links)
- Immune checkpoint inhibitors: therapeutic advances in melanoma (Q26775591) (← links)
- Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma (Q26775769) (← links)
- Promises and paradoxes of regulatory T cells in inflammatory bowel disease (Q26777557) (← links)
- Molecular profiling in the treatment of colorectal cancer: focus on regorafenib (Q26778296) (← links)
- Predictive factors for immunotherapy in melanoma (Q26778765) (← links)
- Advances in immunotherapy for treatment of lung cancer (Q26778790) (← links)
- Relevance of tumor-infiltrating lymphocytes in breast cancer (Q26795598) (← links)
- Antagonists of PD-1 and PD-L1 in Cancer Treatment (Q26796311) (← links)
- The progress of immunotherapy for glioblastoma (Q26797282) (← links)
- The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients (Q26797478) (← links)
- Nivolumab in the treatment of malignant melanoma: review of the literature (Q26798330) (← links)
- The role of microenvironment and immunity in drug response in leukemia (Q26800735) (← links)
- Autoimmune Therapies Targeting Costimulation and Emerging Trends in Multivalent Therapeutics (Q26823789) (← links)
- Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances (Q26827475) (← links)
- Role of the PD-1 pathway in the immune response (Q26828748) (← links)
- The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity (Q26829847) (← links)
- Overcoming T cell exhaustion in infection and cancer (Q26829885) (← links)
- Current advances in immunotherapy for pancreatic cancer (Q26830170) (← links)
- Neutralizing tumor-promoting chronic inflammation: a magic bullet? (Q26830931) (← links)
- Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells (Q26852287) (← links)
- Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer (Q26852704) (← links)
- Melanoma: new insights and new therapies (Q26853127) (← links)